Can Lab-Made wound patches close stubborn pressure sores?
NCT ID NCT06999590
First seen Sep 23, 2026 · Last updated Sep 24, 2026 · Updated 1 time
Summary
Researchers are testing whether adding cellular, acellular, or matrix-like wound products to standard care helps close pressure ulcers that have not healed. The trial enrolls about 500 adults with stage 3 or 4 pressure ulcers on the trunk that have lasted at least a month. Participants receive weekly applications of a wound product plus standard care, or standard care alone, for up to 20 weeks. The main goal is to see how many ulcers fully close in each group.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- cellular, acellular, and matrix-like wound products (ACApatch and caregraFT)
- What this could lead to
- If the products help, they could offer a way to close pressure ulcers that resist standard wound care, possibly reducing healing time and the need for surgery.
- What could go wrong
- Pressure ulcers are stubborn, and adding a wound product to standard care may not speed healing more than standard care alone. The trial may show no clear difference between the products and standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 500 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2025
- Expected to finish
-
May 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. The potential subject must be at least 18 years of age or older. 2. The potential subject must agree to attend the weekly study visits required by the protocol. 3. The potential subject must be willing and able to participate in the informed consent process. 4. The potential subject must have a full-thickness pressure ulcer NPIAP stage 3 or stage 4 without exposed tendon or bone of greater than or equal to one month in duration located on the trunk (sacral, trochanteric, or ischial). 5. At enrollment, the potential subject must have a target ulcer with a minimum surface area of 2 cm2 and a maximum surface area of 100 cm2 measured post-debridement with the imaging device. 6. The potential subject has adequate off-loading of the ulcer. Exclusion Criteria: 1. The potential subject is known to have a life expectancy of \< 3 months. 2. The potential subject's target ulcer is not a pressure ulcer. 3. The target ulcer is infected, requires systemic antibiotic therapy, or there is cellulitis in the surrounding skin. 4. The target ulcer exposes tendon or bone. 5. The target ulcer has undermining or tunneling. 6. There is evidence of osteomyelitis complicating the target ulcer. 7. The potential subject is receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of prednisone per day or equivalent) or cytotoxic chemotherapy or is taking medications that the PI believes will interfere with wound healing (e.g., biologics). 8. The potential subject has applied topical steroids to the ulcer surface within one month of initial screening. 9. The potential subject has glycated hemoglobin (HbA1c) greater than or equal to 12% within 3 months of the initial screening visit. 10. The surface area of the potential subject's target ulcer has reduced in size by more than 20% in the 2 weeks prior to the initial screening visit ("historical" run-in period). Imaging Device is not required for measurements taken during the historical run-in period (e.g., calculating surface area using length X width is acceptable). 11. The surface area measurement of the potential subject's target ulcer decreases by 25% or more during the active 2-week screening phase: the 2 weeks from the initial screening visit (S1) to the TV-1 visit during which time the potential subject received SOC. 12. The potential subject is a woman who is pregnant or considering becoming pregnant within the next 6 months. 13. The potential subject has end stage renal disease requiring dialysis. 14. The potential subject, in the opinion of the investigator, has a medical or psychological condition that may interfere with study assessments. 15. The potential subject was treated with hyperbaric oxygen therapy (HBOT) or a Cellular, Acellular, Matrix-like Product (CAMP) in the 30 days prior to the initial screening visit. 16. The potential subject has a malnutrition indicator score of \<17 as measured on the Mini Nutritional Assessment.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Pressure injury are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Serena Group
RECRUITINGMonroeville, Pennsylvania, 15146, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a gel made from your own blood heal diabetic foot ulcers?
- Can Lab-Made wound patches close stubborn diabetic and leg ulcers?
- Cameras and ultrasound could take the guesswork out of wound care
- Wound dressings that trap microbes: scientists test a Drug-Free approach
- Can a muffin help heal stomach ulcers?
- AI-Crafted care plan aims to stop a common ICU harm